Adaptimmune Therapeutics (ADAP) & Celsion (CLSN) Critical Contrast


Adaptimmune Therapeutics and Celsion are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Adaptimmune Therapeutics currently has a consensus target price of $12.50, indicating a potential upside of 49.34%.



from Biotech News